Nanoparticle-mediated local delivery of pioglitazone attenuates bleomycin-induced skin fibrosis
- 1 January 2019
- journal article
- research article
- Published by Elsevier in Journal of Dermatological Science
- Vol. 93 (1) , 41-49
Abstract
No abstract availableKeywords
Funding Information
- SENSHIN Medical Research Foundation (MTPS20160425013)
This publication has 27 references indexed in Scilit:
- Biomedical applications of biodegradable polymersJournal of Polymer Science Part B: Polymer Physics, 2011
- PPAR-γ Ligands Repress TGFβ-Induced Myofibroblast Differentiation by Targeting the PI3K/Akt Pathway: Implications for Therapy of FibrosisPLOS ONE, 2011
- Animal model of systemic sclerosisThe Journal of Dermatology, 2010
- Scarring Alopecia and the PPAR-γ ConnectionJournal of Investigative Dermatology, 2009
- Rosiglitazone Abrogates Bleomycin-Induced Scleroderma and Blocks Profibrotic Responses Through Peroxisome Proliferator-Activated Receptor-γThe American Journal of Pathology, 2009
- Pioglitazone, a Peroxisome Proliferator-Activated Receptor Gamma Ligand, Suppresses Bleomycin-Induced Acute Lung Injury and FibrosisRespiration, 2008
- Effect of rosiglitazone and 15-deoxy-Δ12,14-prostaglandin J2on bleomycin-induced lung injuryEuropean Respiratory Journal, 2005
- Rapid endo‐lysosomal escape of poly(DL‐lactide‐ co glycolide) nanoparticles: implications for drug and gene deliveryThe FASEB Journal, 2002
- Animal Model of Sclerotic Skin. I: Local Injections of Bleomycin Induce Sclerotic Skin Mimicking SclerodermaJournal of Investigative Dermatology, 1999
- Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/ polyglycolic acid copolymersBiomaterials, 1996